Today, Teva Pharmaceutical Industries Ltd. (TEVA) to Issue Quarterly Dividend of $0.34 on December 20th

Today, Teva Pharmaceutical Industries Ltd. (TEVA) to Issue Quarterly Dividend of $0.34 on  December 20th
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced a quarterly dividend on Tuesday, November 15th. Shareholders of record on Monday, December 5th will be paid a dividend of 0.34 per share on Tuesday, December 20th. This represents a $1.36 dividend on an annualized basis and a yield of 3.56%. The ex-dividend date is Thursday, December 1st.

Shares of Teva Pharmaceutical Industries (NYSE:TEVA) opened at 38.21 on Friday. Teva Pharmaceutical Industries has a 52 week low of $37.12 and a 52 week high of $66.55. The firm has a market cap of $38.78 billion, a price-to-earnings ratio of 22.23 and a beta of 0.73. The firm’s 50-day moving average price is $41.56 and its 200-day moving average price is $49.24.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Tuesday, November 15th. The company reported $1.31 EPS for the quarter, beating analysts’ consensus estimates of $1.29 by $0.02. Teva Pharmaceutical Industries had a return on equity of 16.75% and a net margin of 8.81%. The firm had revenue of $5.56 billion for the quarter, compared to the consensus estimate of $5.71 billion. During the same quarter in the previous year, the company posted $1.35 earnings per share. The business’s quarterly revenue was up 15.3% compared to the same quarter last year. Equities research analysts expect that Teva Pharmaceutical Industries will post $5.14 EPS for the current fiscal year.

A number of research analysts have commented on the company. RBC Capital Markets set a $71.00 target price on Teva Pharmaceutical Industries and gave the company a “buy” rating in a research note on Sunday, September 11th. Bank of America Corp. set a $72.00 price target on Teva Pharmaceutical Industries and gave the stock a “buy” rating in a research report on Saturday, October 1st. Deutsche Bank AG set a $68.00 price target on Teva Pharmaceutical Industries and gave the stock a “buy” rating in a research report on Saturday, October 15th. Piper Jaffray Cos. reaffirmed a “neutral” rating and issued a $57.00 price target (up previously from $55.00) on shares of Teva Pharmaceutical Industries in a research report on Monday, August 8th. Finally, Vetr raised Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating and set a $58.99 price target for the company in a research report on Wednesday, August 10th. Thirteen equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the stock. Teva Pharmaceutical Industries presently has a consensus rating of “Buy” and an average price target of $60.00.

Several large investors have recently added to or reduced their stakes in the stock. Franklin Resources Inc. raised its stake in Teva Pharmaceutical Industries by 11.9% in the second quarter. Franklin Resources Inc. now owns 41,211,549 shares of the company’s stock worth $2,070,095,000 after buying an additional 4,389,590 shares during the period. Waddell & Reed Financial Inc. raised its stake in Teva Pharmaceutical Industries by 4.9% in the second quarter. Waddell & Reed Financial Inc. now owns 19,358,468 shares of the company’s stock worth $972,375,000 after buying an additional 896,033 shares during the period. Janus Capital Management LLC raised its stake in Teva Pharmaceutical Industries by 14.2% in the second quarter. Janus Capital Management LLC now owns 4,577,851 shares of the company’s stock worth $229,933,000 after buying an additional 568,998 shares during the period. State of Tennessee Treasury Department acquired a new stake in Teva Pharmaceutical Industries during the second quarter worth approximately $25,399,000. Finally, Ontario Teachers Pension Plan Board raised its stake in Teva Pharmaceutical Industries by 65.7% in the second quarter. Ontario Teachers Pension Plan Board now owns 1,128,900 shares of the company’s stock worth $56,705,000 after buying an additional 447,600 shares during the period. Institutional investors own 63.16% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Related posts

Leave a Comment